PolarityTE Issues Statement on Misleading Internet Post

SALT LAKE CITY, Oct. 18, 2018 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products for the fields of medicine, biomedical engineering and material sciences, today issued the following statement in response to Citron Research:

The false and misleading assertions made by Citron, a publication well-known to be used as tool by notorious short sellers, are designed to negatively impact PolarityTE's share price for the benefit of short sellers and other colluding agents, and are contrary not only to PolarityTE's view, but also to that of our physician partners, KOLs, and SkinTE patients. As PolarityTE noted in a press release issued on October 9, 2018, unusual and suspected illegal trading activity in the Company's securities has been observed and has been reported to appropriate regulatory authorities. This conduct from Citron?whose founder has been barred from trading on certain exchanges in the past due to manipulative activity?is consistent with a pattern and practice of deliberate distortion to negatively impact PolarityTE. Those engaging in illegal manipulative trading activity such as "short and distort" schemes, "naked short" selling, and pre-arranged trading are accountable under federal laws enforced by the regulators. The Company will not be distracted from its patient-focused mission. Here are the facts:

Technology
PolarityTE remains focused on transforming the lives of patients with regenerative and functional tissue-based solutions, fulfilling a significant unmet need. SkinTE recently transitioned into Stage 2 of commercialization, and the Company's Commercial Target Regional Market release began in July 2018 in major metropolitan regions. SkinTE continues to gain approvals by Value Analysis Committees (VAC) in many hospitals, medical centers, and physician offices nationwide. In fact, our track record here is 100% -- all hospitals, clinics, and practices that have completed their evaluations of the product have initiated purchase agreements with the Company. As a result, the Company continues to grow revenues and our third quarter 2018 financial results exceeded both internal and consensus estimates.

FDA
SkinTEtm is registered with the FDA as is required of human cells, tissues, and cellular and tissue-based products ("HCT/P") and regulated solely under Section 361 of the Public Health Service Act (i.e., as a "361 HCT/P"). PolarityTE is subject to routine post-market regulation, including facility inspections, by the FDA.  PolarityTE does not comment on non-final observations related to interactions with the FDA that are part of the routine regulatory process.  The Company has responded to the non-final observations and will continue to follow any guidance provided by the FDA.

Patent Application
Citron's statements about PolarityTE's patent applications (on which its first report was predicated) demonstrate at best clear lack of understanding about the patent application process, or a deliberate attempt to mislead investors and the public. Citron continues to portray the "final rejection" of one patent as a material event. In fact, what is called a "final rejection" (which patent experts consider misleading terminology) is a normal part of the patent application and approval process. According to a leading patent attorney and commentator on patent law, "Only those who are completely unfamiliar with patent practice and procedure could possibly make such an erroneous claim."¹ Contrary to what Citron misleadingly suggests, the Company has responded to the USPTO and its patent prosecution continues on the referenced application as well as multiple additional applications. 

Governance
Citron has also continued to focus on a number of individuals who are no longer affiliated with PolarityTE's Board of Directors or management. PolarityTE has an independent Board, composed of eight highly-qualified directors, all of whom were appointed in the past two years and six of whom are independent, who together bring a wide variety of biotechnology, regenerative medicine, healthcare delivery, operations, governance and finance expertise that is critical to PolarityTE's business. Since July 2018, the Company has appointed three new members to its Board, including Peter Cohen, former Board Member of the New York Stock Exchange (NYSE) and Chairman and CEO of Cowen Inc.; Ramses (Rainer) Erdtmann, Managing Partner at Point Sur Investors and formerly an executive at Pharmacyclics; and David Seaburg, Managing Director at Cowen.

PolarityTE is a company founded by healthcare providers and remains focused on its mission to create innovative and life-changing products to improve humanity.

About PolarityTE®
PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The PolarityTE platform technology begins with a small piece of the patient's own, or autologous, healthy tissue, rather than artificially manipulated individual cells. From this small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to enhance and stimulate the patient's own cells to regenerate the target tissues. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient's own tissue and uses the patient's own body to support the regenerative process to create the same tissue from which it was derived. PolarityTE's innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing.

Forward Looking Statements
Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as "believes," "may," "expects," "anticipates," "intend," "plan," "will," "would," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. Our actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov).

POLARITYTE, the POLARITYTE logo, and SKINTE are all trademarks or registered trademarks of PolarityTE, Inc.

CONTACTS:

Investors:
Rich Haerle
PolarityTE, Inc.
VP of IR & Corporate Strategy
[email protected]
(385) 831-5284

Hans Vitzthum 
LifeSci Advisors, LLC
[email protected]
(617) 535-7743

Media:
Jenna Mathis
PolarityTE, Inc.
[email protected]
(610) 751-3985

¹ Gene Quinn, IPWatchdog. Permission to use quote neither sought nor obtained.

SOURCE PolarityTE, Inc.